Role of adalimumab in the treatment of early rheumatoid arthritis. Academic Article uri icon

Overview

abstract

  • Adalimumab, a recent addition to the therapeutic armamentarium in rheumatoid arthritis (RA), has been evaluated in patients with early RA. The DE019 study, a double blind randomized placebo controlled trial of adalimumab given 20 mg once a week or 40 mg every other week demonstrated both clinical and radiographic efficacy. A subset analysis of patients with early disease revealed that early treatment with adalimumab may be more efficacious than therapy later in the course of disease, particularly with regard to radiographic progression. The findings support early aggressive intervention in RA.

publication date

  • September 1, 2003

Research

keywords

  • Antibodies, Monoclonal
  • Arthritis, Rheumatoid

Identity

Scopus Document Identifier

  • 0142124929

PubMed ID

  • 14969077

Additional Document Info

volume

  • 21

issue

  • 5 Suppl 31